LONDON, Dec. 07, 2017 -- A new report from Meticulous Research™, titled as ‘Bone Growth Stimulator Market – Global Opportunity Analysis and Industry Forecast (2017-2022)’, cites the worldwide bone growth stimulator market to reach USD $1,397.6 Million by 2022, growing at a CAGR of 5.8% during the forecast period.
“The bone growth stimulator market is driven by growing geriatric population with the prevalence of orthopaedic issues and rising preference for stimulation treatments. Moreover, emerging economies such as Latin America, Asia, and Africa provides significant opportunities in this market,” mentions Meticulous Research™.
The report also states that, on the basis of application, spinal fusion surgeries share the largest bone growth stimulator market due to “rising number of spine procedures with increasing risk of orthopedic problems; increasing bone related injuries by growing number of road accidents, trauma and sport activities; and rising adoption of bone growth stimulation products due to decreasing normal bone healing process with increase in the age”.
Request Sample Report: http://www.meticulousresearch.com/request-sample-report/?cp_id=3530
North America (mainly U.S and Canada) currently have the largest share of the bone growth stimulator market, “due to remarkably advanced healthcare industry with higher healthcare spending and adoption of innovative science & technology; increasing prevalence & incidence of orthopedic diseases such as osteoarthritis, chronic back & neck pain, rheumatoid arthritis, and others with expanding proportion of elderly population; and availability of research funding.”
The key players in this market are Orthofix International N.V., DJO Global, Inc., Zimmer Biomet Holdings, Inc., Medtronic, plc, Johnson & Johnson, Stryker Corporation, Bioventus Inc., Arthrex, Inc., ISTO Biologics, Ossatec Benelux Ltd., Regen Lab SA, ITO CO., Ltd., Altis Biologics (Pty) Ltd, and Harvest Technologies Corporation.
Full News: http://www.meticulousresearch.com/bone-growth-stimulator-market-forecast/
Scope of the report
Market by Product
• Bone Growth Stimulation Devices
• External Bone Growth Stimulator
- Pulsed Electromagnetic Field Devices
- Capacitive Coupling Devices
- Combined Magnetic Field Devices
• Implanted Bone Growth Stimulators
• Ultrasonic Bone Growth Stimulators
• Bone Morphogenetic Proteins
• Platelet Rich Plasma
Market by Application
• Spinal Fusion Surgeries
• Delayed Union & Non-union Bone Fractures
• Oral and Maxillofacial Bone surgeries
• Others
Market by End User
• Hospitals & Clinics
• Academic and Research Institutes
• Contract Research Organizations
• Home Care
Browse in-depth report on http://www.meticulousresearch.com/product/bone-growth-stimulator-market-2022/
Contact Info:
Viren Shrivastava
Email: [email protected]
Direct Lines: +1-646-781-8004 (North America)
+44-203-868-8738 (Europe)
+91 744-7780008 (Asia-Pacific)


Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



